WuXi Biologics Achieves Record Growth and Digital Transformation in 2025 In 2025, WuXi Biologics reported record revenue growth driven by digital transformation, enhancing operational efficiency and client collaboration.

WuXi Biologics Achieves Record Growth and Digital Transformation in 2025 #China #Shanghai #Digital_Transformation #WuXi_Biologics #CRDMO

WuXi XDC Reports Impressive Growth in 2025, Solidifying Its Position in Bioconjugate CRDMO Market WuXi XDC’s 2025 financial performance reflects significant growth in revenue and market position, underscoring its role in bioconjugate CRDMO.

WuXi XDC Reports Impressive Growth in 2025, Solidifying Its Position in Bioconjugate CRDMO Market #China #Shanghai #WuXi_XDC #bioconjugate #CRDMO

Syngene International Extends Strategic Partnership with Bristol Myers Squibb Until 2035 Syngene International has announced a contract extension with Bristol Myers Squibb that will last until 2035, strengthening their collaboration in drug development.

Syngene International Extends Strategic Partnership with Bristol Myers Squibb Until 2035 #India #Bengaluru #Bristol_Myers_Squibb #Syngene_International #CRDMO

WuXi AppTec's Strong Financial Forecasts Indicate Significant Growth Ahead for 2025 WuXi AppTec announces promising projections for 2025, expecting revenue growth of 21.4% and a remarkable rise in net profit, reflecting its commitment to expanding healthcare innovations.

WuXi AppTec's Strong Financial Forecasts Indicate Significant Growth Ahead for 2025 #China #Shanghai #healthcare #WuXi_AppTec #CRDMO

WuXi AppTec Honored as 2025 Global Company of the Year in CRDMO Sector WuXi AppTec has been recognized as the 2025 Global Company of the Year by Frost & Sullivan for its excellence in the CRDMO industry, highlighting its significant innovations and strategies.

WuXi AppTec Honored as 2025 Global Company of the Year in CRDMO Sector #USA #San_Antonio #Frost_&_Sullivan #WuXi_AppTec #CRDMO

WuXi AppTec Achieves Milestone with Frost & Sullivan's 2025 Global Company Award in CRDMO Sector WuXi AppTec has been honored with Frost & Sullivan's 2025 Global Company of the Year Award, marking a significant achievement in the CRDMO industry.

WuXi AppTec Achieves Milestone with Frost & Sullivan's 2025 Global Company Award in CRDMO Sector #China #Shanghai #Frost_&_Sullivan #WuXi_AppTec #CRDMO

WuXi XDC Achieves Remarkable Wins at 2025 World ADC Awards for CDMO and CRO WuXi XDC has secured top honors at the 2025 World ADC Awards, winning 'Best CDMO' and 'Best CRO.' These accolades highlight its leadership in the bioconjugate industry.

WuXi XDC Achieves Remarkable Wins at 2025 World ADC Awards for CDMO and CRO #China #Shanghai #WuXi_XDC #CRDMO #ADC_Awards

WuXi AppTec Reports Impressive Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 WuXi AppTec has shown remarkable growth in revenue and profit for the first three quarters of 2025, along with a significant increase in backlog and strong financial performance.

WuXi AppTec Reports Impressive Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 #China #Shanghai #financial_results #WuXi_AppTec #CRDMO

WuXi Biologics Showcases Strong Financial Performance in 2025 Interim Results WuXi Biologics reports impressive interim results for 2025, highlighting growth in revenue, profit margins, and project completions. The company strengthens its position in the biotech industry.

WuXi Biologics Showcases Strong Financial Performance in 2025 Interim Results #None #WuXi_Biologics #Biologics #CRDMO

WuXi XDC Reports Strong Revenue Growth and Continued Market Leadership in Bioconjugates for H1 2025 WuXi XDC showcases impressive financial performance in the first half of 2025, highlighting significant growth in revenue and market expansion in the bioconjugates sector.

WuXi XDC Reports Strong Revenue Growth and Continued Market Leadership in Bioconjugates for H1 2025 #China #Shanghai #WuXi_XDC #CRDMO #bioconjugates

WuXi XDC Celebrates Inclusion in MSCI China All Share Index Marking a New Milestone WuXi XDC, a leading Contract Research Organization, has been included in the MSCI China All Share Index, enhancing its exposure in global markets.

WuXi XDC Celebrates Inclusion in MSCI China All Share Index Marking a New Milestone #China #Shanghai #WuXi_XDC #CRDMO #MSCI_China

WuXi AppTec's Recognition in Extel's 2025 Asia Leadership Rankings WuXi AppTec has been awarded top honors in Extel's 2025 leadership rankings, affirming its quality service in healthcare and innovation.

WuXi AppTec's Recognition in Extel's 2025 Asia Leadership Rankings #China #Shanghai #WuXi_AppTec #CRDMO #Extel_Rankings

WuXi AppTec Achieves Top Recognition in 2025 Asia Executive Team Rankings WuXi AppTec has been awarded top positions in Extel's 2025 Asia Executive Team Rankings, highlighting its impact in the pharmaceutical industry.

WuXi AppTec Achieves Top Recognition in 2025 Asia Executive Team Rankings #China #Shanghai #WuXi_AppTec #CRDMO #Asia_Executive_Team

WuXi XDC Earns Six Prestigious Awards at 2025 Extel Rankings for Leadership and Governance WuXi XDC has achieved remarkable recognition by securing multiple prestigious awards at the 2025 Extel Rankings, showcasing its leadership and governance excellence in the bioconjugate sector.

WuXi XDC Earns Six Prestigious Awards at 2025 Extel Rankings for Leadership and Governance #China #Shanghai #WuXi_XDC #CRDMO #Extel_Awards

WuXi Biologics Unveils 2024 Sustainability Report, Highlights Commitment to Responsible Innovation WuXi Biologics has released its 2024 Sustainability Report, reinforcing its commitment to environmental stewardship, transparency, and community empowerment in the biopharmaceutical sector.

WuXi Biologics Unveils 2024 Sustainability Report, Highlights Commitment to Responsible Innovation #Hong_Kong #WuXi_Biologics #Sustainability_Report #CRDMO

WuXi Biologics Achieves Remarkable Recognition at Asia-Pacific Biopharma Awards WuXi Biologics has claimed five prestigious awards at the 2025 Asia-Pacific Biopharma Excellence Awards, marking a significant achievement in the biopharmaceutical industry.

WuXi Biologics Achieves Remarkable Recognition at Asia-Pacific Biopharma Awards #China #Shanghai #Biopharma #WuXi_Biologics #CRDMO